Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
- PMID: 31835496
- PMCID: PMC6966476
- DOI: 10.3390/cancers11121988
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
Abstract
Recent advances in high-throughput molecular and multi-omics technologies have improved our understanding of the molecular changes associated with thyroid cancer initiation and progression. The translation into clinical use based on molecular profiling of thyroid tumors has allowed a significant improvement in patient risk stratification and in the identification of targeted therapies, and thereby better personalized disease management and outcome. This review compiles the following: (1) the major molecular alterations of the genome, epigenome, transcriptome, proteome, and metabolome found in all subtypes of thyroid cancer, thus demonstrating the complexity of these tumors and (2) the great translational potential of multi-omics studies to improve patient outcome.
Keywords: genomic; methylation; microRNA; proteomic; thyroid cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
